A Phase 1 trial in China is recruiting multiple myeloma patients who failed prior treatments to study…
Articles by Inês Martins, PhD
Heavily treated multiple myeloma patients included in the first four dosing groups of Cellectar Biosciences’ Phase 1 trial lived for…
Long-term maintenance treatment with Revlimid (lenalidomide) significantly improves the length of time multiple myeloma patients live without disease…
Multiple myeloma patients who are not eligible for high-dose chemotherapy and stem cell transplant significantly benefit from the addition of Darzalex…
Updated results from a Phase 2b clinical trial continue to support Karyopharm Therapeutics‘ investigative oral therapy selinexor (KPT-330) as a promising…
The European Commission has approved the anti-CD38 antibody Darzalex (daratumumab), in combination with standard therapy, for newly diagnosed multiple myeloma…
Prescribing information for Kyprolis (carfilzomib) in the U.S. will now include positive survival data from the ASPIRE Phase 3 clinical…
A Phase 1b trial testing a combination of Reolysin (pelareorep), Velcade (bortezomib) and dexamethasone in multiple myeloma patients who failed…
Trillium Therapeutics recently dosed the first patient in its Phase 1 clinical trial of TTI-622, a checkpoint inhibitor of…
Janssen recently initiated a Phase 1b/2 clinical development program to evaluate JNJ-68284528, a chimeric antigen receptor (CAR) T-cell therapy,…